PUBLISHER: The Business Research Company | PRODUCT CODE: 1427914
PUBLISHER: The Business Research Company | PRODUCT CODE: 1427914
Multiple Myeloma Drugs Global Market Report 2024
Multiple myeloma pharmaceuticals are medications designed for the treatment of multiple myeloma and related malignancies affecting plasma cells within the bone marrow. These therapeutic agents are specifically formulated to manage skeletal complications associated with myeloma, including pamidronate (Aredia) and zoledronic acid (Zometa).
Key therapeutic categories for multiple myeloma encompass immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibody therapies, corticosteroids, among others. Targeted therapy represents an innovative approach in oncology, leveraging drugs or compounds to directly engage essential molecular targets pivotal for cancer cell viability and growth. In the context of multiple myeloma, these treatments are tailored to engage specific molecules, such as intracellular proteins, which modulate cellular signaling pathways promoting proliferation. Various therapeutic modalities include targeted therapy, biologic interventions, chemotherapy, among others, with diverse distribution channels encompassing hospital-based pharmacies, community retail pharmacies, online pharmaceutical platforms, and other avenues, catering to both male and female patient demographics.
The multiple myeloma drugs market research report is one of a series of new reports from The Business Research Company that provides multiple myeloma drugs market statistics, including multiple myeloma drugs industry global market size, regional shares, competitors with a multiple myeloma drugs market share, detailed multiple myeloma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma drugs industry. This multiple myeloma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $20.7 billion in 2023 to $22.09 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth observed during the historical period can be ascribed to advancements in diagnostic capabilities, successful outcomes in clinical trials, enhanced comprehension of disease biology, improvements in healthcare infrastructure, as well as increased patient advocacy and awareness.
The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $28.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period is linked to ongoing innovations in immunotherapy, the expanding reach of targeted therapies, increased applications of liquid biopsy techniques, the emergence of CAR-T cell therapy, and continuous progress in biomarker discovery. Noteworthy trends expected in the forecast period encompass a heightened focus on long-term survivorship, exploration of epigenetic therapies, a broader role for telemedicine, increased accessibility to novel therapeutic approaches, and a growing emphasis on sustainability in myeloma care.
The anticipated growth of the multiple myeloma drugs market is expected to be driven by the increasing prevalence of hematological cancer. Hematological cancers, originating in blood-forming tissues such as bone marrow or immune system cells, include conditions such as leukemia, lymphoma, multiple myeloma, among others. Multiple myeloma medications play a crucial role in treating these cancers by inhibiting the growth of cancer cells, reducing cell division, stimulating various enzymatic activities, and contributing to bone strength, thereby alleviating pain associated with bone weakening. As of January 2023, the American Cancer Society reported approximately 59,610 newly diagnosed cases of leukemia, with around 20,380 cases of acute myeloid leukemia (AML) and 23,710 deaths attributed to leukemia. The rising incidence of hematological cancer underscores the growing demand for multiple myeloma drugs.
The progress in biotechnology and precision medicine is expected to significantly contribute to the market's growth. Biotechnology, involving the application of biological systems to develop innovative products, and precision medicine, a personalized healthcare approach tailored to individual characteristics such as genetics and molecular profile, are instrumental in utilizing multiple myeloma drugs. These advanced technologies leverage genetic and molecular insights to identify targeted therapies personalized for individual patients, thereby optimizing treatment effectiveness. As of October 2022, estimates from the Personalized Medicine Coalition indicated that over 75,000 genetic testing kits and 300 personalized treatments would be available for various cancers, hereditary disorders, and chronic diseases. The continued advancement in biotechnology and precision medicine is a driving force behind the expansion of the multiple myeloma drugs market.
Product innovation is a key trend gaining popularity in the multiple myeloma drugs market. Major companies operating in the multiple myeloma drugs market are focused on developing innovative products to strengthen their Product innovation emerges as a prominent trend shaping the landscape of the multiple myeloma drugs market, with major industry players prioritizing the development of novel products to enhance their market standing and gain a competitive edge. A case in point is Janssen Biotech Inc., a Japanese biotechnology company, which secured approval from the United States Food and Drug Administration in March 2022 for Carvykti, a CAR T-Cell therapy designed for multiple myeloma treatment. Carvykti, utilizing genetically modified autologous T cells, features a chimeric antigen receptor (CAR) targeting B cell maturation antigen (BCMA). Eligible patients, having undergone multiple lines of therapy, including essential myeloma medications, can receive this therapy for the management of relapsed conditions.
Strategic partnerships represent another key approach adopted by major companies in the multiple myeloma drugs market to collaboratively develop and commercialize innovative products. An exemplar is the collaboration between Kite Pharma, a subsidiary of Gilead Sciences Inc., a US-based pharmaceutical company, and Arcellx, a US-based biotechnology company. Their partnership, established in December 2022, focuses on the joint development and commercialization of Arcellx's T-cell therapy, CART-ddBCMA, targeting relapsed or refractory multiple myeloma patients. This therapy incorporates Arcellx's unique D-Domain binder and involves autologous T cells genetically modified for effective multiple myeloma targeting.
In November 2021, Pfizer Inc., a leading pharmaceutical manufacturer headquartered in the United States, successfully completed the acquisition of Trillium Therapeutics for an undisclosed financial amount. This strategic acquisition is part of Pfizer's overarching objective to fortify its oncology portfolio by incorporating cutting-edge and experimental immunotherapies specifically designed for the treatment of hematological cancers. Trillium Therapeutics Inc., the target of the acquisition, is a Canada-based biopharmaceutical company specializing in the development and production of innovative drugs for the treatment of multiple myeloma, a form of hematological cancer.
Major companies operating in the multiple myeloma drugs market report are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc., Amgen Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB
North America was the largest region in the multiple myeloma drugs market in 2023. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the multiple myeloma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The multiple myeloma drugs market consists of revenues earned by entities by providing various therapies such radiation therapy, bone-marrow transplant, surgery and stem-cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma drug market also includes sales of nuclear export inhibitors, bispecific T cell engager (BiTE), bisphosphonates, and alkylating agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Multiple Myeloma Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on multiple myeloma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for multiple myeloma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple myeloma drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
- 1) By Drug Type: Immunomodulatory Drugs; Proteasome Inhibitors; Histone Deacetylase Inhibitors; Monoclonal Antibody Drugs; Steroids; Other Drug Types
- 2) By Therapy: Targeted Therapy; Biologic Therapy; Chemotherapy; Other Therapies
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
- 4) By End-User: Men; Women
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Pvt. Ltd; Merck & Co. Inc.; AbbVie Inc.; Bayer AG.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Multiple Myeloma Drugs Market Characteristics
3. Multiple Myeloma Drugs Market Trends And Strategies
4. Multiple Myeloma Drugs Market - Macro Economic Scenario
- 4.1. Impact Of High Inflation On The Market
- 4.2. Ukraine-Russia War Impact On The Market
- 4.3. COVID-19 Impact On The Market
5. Global Multiple Myeloma Drugs Market Size and Growth
- 5.1. Global Multiple Myeloma Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
- 5.2. Global Multiple Myeloma Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
- 5.3. Global Multiple Myeloma Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Multiple Myeloma Drugs Market Segmentation
- 6.1. Global Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Other Drug Types
- 6.2. Global Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Other Therapies
- 6.3. Global Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- 6.4. Global Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Men
- Women
7. Multiple Myeloma Drugs Market Regional And Country Analysis
- 7.1. Global Multiple Myeloma Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 7.2. Global Multiple Myeloma Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Multiple Myeloma Drugs Market
- 8.1. Asia-Pacific Multiple Myeloma Drugs Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.3. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.4. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Multiple Myeloma Drugs Market
- 9.1. China Multiple Myeloma Drugs Market Overview
- 9.2. China Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.3. China Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.4. China Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Multiple Myeloma Drugs Market
- 10.1. India Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.2. India Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.3. India Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Multiple Myeloma Drugs Market
- 11.1. Japan Multiple Myeloma Drugs Market Overview
- 11.2. Japan Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.3. Japan Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.4. Japan Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Multiple Myeloma Drugs Market
- 12.1. Australia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.2. Australia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.3. Australia Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Multiple Myeloma Drugs Market
- 13.1. Indonesia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.2. Indonesia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.3. Indonesia Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Multiple Myeloma Drugs Market
- 14.1. South Korea Multiple Myeloma Drugs Market Overview
- 14.2. South Korea Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.3. South Korea Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.4. South Korea Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Multiple Myeloma Drugs Market
- 15.1. Western Europe Multiple Myeloma Drugs Market Overview
- 15.2. Western Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.3. Western Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.4. Western Europe Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Multiple Myeloma Drugs Market
- 16.1. UK Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.2. UK Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.3. UK Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Multiple Myeloma Drugs Market
- 17.1. Germany Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.2. Germany Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.3. Germany Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Multiple Myeloma Drugs Market
- 18.1. France Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.2. France Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.3. France Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Multiple Myeloma Drugs Market
- 19.1. Italy Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.2. Italy Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.3. Italy Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Multiple Myeloma Drugs Market
- 20.1. Spain Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.2. Spain Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.15. Spain Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Multiple Myeloma Drugs Market
- 21.1. Eastern Europe Multiple Myeloma Drugs Market Overview
- 21.2. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.3. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.4. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Multiple Myeloma Drugs Market
- 22.1. Russia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.2. Russia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.3. Russia Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Multiple Myeloma Drugs Market
- 23.1. North America Multiple Myeloma Drugs Market Overview
- 23.2. North America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.3. North America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.4. North America Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Multiple Myeloma Drugs Market
- 24.1. USA Multiple Myeloma Drugs Market Overview
- 24.2. USA Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.3. USA Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.4. USA Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Multiple Myeloma Drugs Market
- 25.1. Canada Multiple Myeloma Drugs Market Overview
- 25.2. Canada Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.3. Canada Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.4. Canada Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Multiple Myeloma Drugs Market
- 26.1. South America Multiple Myeloma Drugs Market Overview
- 26.2. South America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.3. South America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.4. South America Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Multiple Myeloma Drugs Market
- 27.1. Brazil Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.2. Brazil Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.3. Brazil Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Multiple Myeloma Drugs Market
- 28.1. Middle East Multiple Myeloma Drugs Market Overview
- 28.2. Middle East Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.3. Middle East Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.4. Middle East Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Multiple Myeloma Drugs Market
- 29.1. Africa Multiple Myeloma Drugs Market Overview
- 29.2. Africa Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.3. Africa Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.4. Africa Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Multiple Myeloma Drugs Market Competitive Landscape And Company Profiles
- 30.1. Multiple Myeloma Drugs Market Competitive Landscape
- 30.2. Multiple Myeloma Drugs Market Company Profiles
- 30.2.1. Pfizer Inc.
- 30.2.1.1. Overview
- 30.2.1.2. Products and Services
- 30.2.1.3. Strategy
- 30.2.1.4. Financial Performance
- 30.2.2. Johnson & Johnson Pvt. Ltd
- 30.2.2.1. Overview
- 30.2.2.2. Products and Services
- 30.2.2.3. Strategy
- 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
- 30.2.3.1. Overview
- 30.2.3.2. Products and Services
- 30.2.3.3. Strategy
- 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
- 30.2.4.1. Overview
- 30.2.4.2. Products and Services
- 30.2.4.3. Strategy
- 30.2.4.4. Financial Performance
- 30.2.5. Bayer AG.
- 30.2.5.1. Overview
- 30.2.5.2. Products and Services
- 30.2.5.3. Strategy
- 30.2.5.4. Financial Performance
- 30.2.1. Pfizer Inc.
31. Multiple Myeloma Drugs Market Other Major And Innovative Companies
- 31.1. Roche Holding AG
- 31.2. Novartis AG
- 31.3. Sanofi S.A.
- 31.4. Bristol-Myers Squibb Company
- 31.5. GlaxoSmithKline Plc
- 31.6. Takeda Pharmaceutical Company Limited
- 31.7. Eli Lilly and Company
- 31.8. Kite Pharma Inc
- 31.9. Amgen Inc.
- 31.10. AstraZeneca plc
- 31.11. Teva Pharmaceutical Industries Ltd.
- 31.12. Regeneron Pharmaceuticals Inc.
- 31.13. Daiichi Sankyo Company
- 31.14. Daiichi Sankyo Co. Ltd.
- 31.15. Lonza Group AG
32. Global Multiple Myeloma Drugs Market Competitive Benchmarking
33. Global Multiple Myeloma Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Multiple Myeloma Drugs Market
35. Multiple Myeloma Drugs Market Future Outlook and Potential Analysis
- 35.1 Multiple Myeloma Drugs Market In 2028 - Countries Offering Most New Opportunities
- 35.2 Multiple Myeloma Drugs Market In 2028 - Segments Offering Most New Opportunities
- 35.3 Multiple Myeloma Drugs Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
